Colchicenamide is a synthetic derivative of colchicine, a natural product with anti-inflammatory and antimitotic properties. It exhibits enhanced potency compared to colchicine in inhibiting tubulin polymerization, a key process in cell division. Colchicenamide has shown promising preclinical activity against various cancers, including leukemia, lymphoma, and breast cancer. Its mechanism of action involves binding to tubulin and disrupting microtubule formation, thereby inhibiting cell proliferation and inducing apoptosis. The compound is currently in clinical trials for the treatment of cancer.'
colchicenamide: RN given refers to (S)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 18397 |
| CHEMBL ID | 357889 |
| SCHEMBL ID | 12118701 |
| MeSH ID | M0079432 |
| Synonym |
|---|
| colchicine amide |
| colchiceeinamide [german] |
| brn 2824077 |
| acetamide, n-(10-amino-5,6,7,9-tetrahydro-1,2,3-trimethoxy-9-oxobenzo(a)heptalen-7-yl)-, (s)- |
| colchicenamide |
| 14-aminocolchicide |
| nsc 403144 |
| colchicamide (van) |
| nsc-403144 |
| colchicide, 14-amino- |
| acetamide,6,7,9-tetrahydro-1,2,3-trimethoxy-9-oxobenzo[a]heptalen-7-yl)-, (s)- |
| colchicamide (colchiceinamide) |
| skf 3192 |
| colchicamide |
| 3123-89-5 |
| colchicine, 10-amino-10-demethoxy- |
| colchiceinamid |
| colchiceinamide |
| nsc403144 |
| colchicamid |
| CHEMBL357889 |
| n-[(7s)-10-amino-1,2,3-trimethoxy-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide |
| 4-14-00-00921 (beilstein handbook reference) |
| colchiceeinamide |
| SCHEMBL12118701 |
| DTXSID00185149 |
| AKOS030489333 |
| n-[(7s)-10-amino-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide |
| STL530408 |
| mfcd25368469 |
| acetamide,n-[(7s)-10-amino-5,6,7,9-tetrahydro-1,2,3-trimethoxy-9-oxobenzo[a]heptalen-7-yl]- |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1527064 | Induction of P-gp in human LS180 cells assessed as increase in intracellular accumulation of Rh123 at 100 nM using Rho123 as substrate preincubated for 48 hrs followed by addition of Rh123 and measured after 90 mins by fluorescence based assay relative to | 2020 | European journal of medicinal chemistry, Jan-01, Volume: 185 | Recent developments on (-)-colchicine derivatives: Synthesis and structure-activity relationship. |
| AID1527066 | Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay | 2020 | European journal of medicinal chemistry, Jan-01, Volume: 185 | Recent developments on (-)-colchicine derivatives: Synthesis and structure-activity relationship. |
| AID1527065 | Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay | 2020 | European journal of medicinal chemistry, Jan-01, Volume: 185 | Recent developments on (-)-colchicine derivatives: Synthesis and structure-activity relationship. |
| AID1674014 | Cytotoxicity against human HeLa cells after 24 to 72 hrs by Cell Titer Blue assay | 2020 | Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19 | Colchicine Alkaloids and Synthetic Analogues: Current Progress and Perspectives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.24) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (28.57%) | 6.00% |
| Case Studies | 1 (14.29%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||